Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GyneRep: RP-6306 + Carboplatin + Paclitaxel in Recurrent TP53 Ovarian and Uterine Cancer
NCT06107868Phase 1Active, not recruiting
- Sponsor
- University Health Network
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lunresertib in ovarian cancer and uterine cancer (2 arms), sponsored by University Health Network. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Mar 2024; status: active, not recruiting.
02
Drugs
lunresertib
03
Conditions
ovarian canceruterine cancer
Beyond the preview
Go deeper on NCT06107868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107868.